INTRODUCTION

An agonist to the G-protein coupled receptor 119 (GPR119) has recently emerged as a promising new anti-diabetic drug target. GPR119 agonist offers promise in modulating glucose homeostasis in an incretin-dependent and incretin-independent manner (Jones and Leonard, 2009). Impaired insulin sensitivity causes chronic hyperglycemia which presents as Type 2 diabetes mellitus (T2DM) (DeFronzo et al., 1992; Taylor et al., 1994). Depletion of glucose-stimulated insulin secretion (GSIS) is a representative feature and leads to post-prandial hyperglycemia in T2DM patients, especially in the early phase (Meece, 2007). In a clinical study, hypoglycemic agents such as metformin, α-glycosidase inhibitors, thiazolidinedines (TZDs) and sulfonylurea derivatives are used. However, these compounds have side effects including hypoglycemia, weight-gain, and cardiovascular problems (Ho et al., 2011). The development of novel diabetes medications, especially oral medications that do not have the side effects of the earlier medications is an active area of research both in the industry and in academics in order to meet the needs of diabetic patients (Xia et al., 2011).

GPR119 agonist is currently receiving significant attention for its therapeutic potential as an anti-diabetic agent and an appropriate treatment modality for the safe amelioration of metabolic diseases. In principle, a molecule acting via GPR119 to raise intracellular cAMP concentrations in pancreatic β-cells would be expected to potentiate glucose-stimulated insulin secretion from human GPR119 receptor stably expressing cells (CHO cells). GLP-1 analogs increase glucose-dependent insulin secretion through the gastrointestinal mechanism, which causes GLP-1 release from pancreatic β-cells and enteroendocrine L-cells due to activation of GPR119. Activation of GPR119 increases GLP-1 levels (Ross and...
In vitro experiments
MATERIALS AND METHODS

In vitro experiments

In the current research, the in vivo efficacy profile of the oral dose of HD047703, a novel small-molecule GPR119 agonist, was evaluated in normal and diabetic mice. HD047703 was synthesized at Hyundai Pharm. We specifically compared the effects of HD047703 with those of the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, which also increases the GLP-1 level in the blood (Barnett, 2006), on glycemic control and insulin secretion in several animal models.

MATERIALS AND METHODS

Chemicals and animals

HD047703 was synthesized in-house at Hyundai Pharm Inc. HD047703 is composed of pyridinone derivatives (Patent No.: WO2012011707). Prior to their use in assays, HD047703 and sitagliptin (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in 0.5% carboxy-methylcellulose (CMC; Sigma-Aldrich, St. Louis, MO, USA).

In vitro experiments

Cell line: Human GPR119 receptor stable cell lines were purchased from ChanTest (Cleveland, Ohio, USA). These cell lines were cultured in Ham’s F12 media containing 10% FBS; 1% Non Essential Amino Acids (NEAA, Gibco), 400 μg/ml G418 (Sigma-Aldrich, St. Louis, MO, USA).

cAMP measurement: Human GPR119 receptor CHO stable cell lines were seeded in 96-well plates at densities of 2×10^4 cells/0.1 ml/well and 5×10^4 cells/0.1 ml/well. After overnight incubation, the cells were incubated for 10 min with the test medium of Hanks buffered salt solution (HBSS; Gibco) containing 5 mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Gibco), 0.5 mM of 3-isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich, St. Louis, MO, USA), and 0.1% of bovine serum albumin (BSA; Sigma-Aldrich). Then, cells were treated with 10, 2, 0.4, 0.08, 0.016, 0.0032 μM concentrations of the test drug for 90 min. Measurement of cytoplasmic cAMP levels after the drug treatment was performed with homogeneous time-resolved fluorescence (HTRF). All data represent the means ± SEM from at least three independent experiments.

Animals

All procedures involving animals were approved by the Animal Ethics Committee of Hyundai Pharm Inc. All animals were housed singly under a 12 hr/12 hr light/dark cycle and free-feeding conditions, in temperature and humidity controlled rooms. Normal C57BL/6J male mice, db/db, and ob/ob mice were obtained from NARA BIO Inc. (Seoul, KOR) and Korea Research Institute of Bioscience and Biotechnology (KRIBB; Ochang, KOR). To generate diet-induced obese (DIO) mice, 4-week-old, normal C57BL/6J mice were fed high-fat chow (Kcal 60% fat) for 8 weeks. The body weight of mice that were fed high-fat diet was checked, and mice with a body weight of more than 40 g were considered as the DIO model.

Efficacy of repeated administration: The studies for assessing chronic efficacy were performed in diabetic mice. The efficacy of HD047703 on glycemic control and insulin secretion in diabetic mice was compared with that of sitagliptin. After 8 weeks of treatment, body weight and blood glucose levels were monitored, and the results were analyzed by one-way ANOVA followed by Dunnett’s multiple comparison test.

In vivo experiments

Oral glucose tolerance test (OGTT) and GLP-1 measurement: Acute pharmacological efficacy of the test drug was tested by the oral glucose tolerance test (OGTT). Eight-week-old male C57BL/6 J mice were fasted overnight and then they were orally administered 0.5% CMC (vehicle) or 10, 50 mg/kg HD047703 through 10 ml/kg. After 30 min, glucose was given orally at a dose of 2 g/kg/10 ml, and blood samples were collected. Blood glucose levels were then monitored by tail snipping at -30, 0, 20, 40, 60, and 120 minutes after glucose loading. The plasma glucose level was immediately determined using Accu-Chek Active blood glucose meter (Roche, Switzerland).

To assess the improvement in active GLP-1 secretion abilities after administration of the test drug, separate experiments were performed in overnight-fasted mice. Thirty minutes following the administration of the test drug, a glucose bolus was administered, and then plasma samples were obtained after 20 min. The isolated plasma was analyzed with active GLP-1 Enzyme-linked immunosorbent assay (ELISA; Millipore, MO, USA).

Efficacy of repeated administration: The studies for assessing chronic efficacy were performed in db/db, ob/ob, and DIO mice. All of the animals were given the vehicle or the test drug bid and sitagliptin qd. To generate the DIO mice, 4-week-old, normal C57BL/6J mice were fed high-fat chow (Kcal 60% fat) for 8 weeks. The body weight of mice that were fed high-fat diet was checked, and mice with a body weight of more than 40 g were considered as the DIO model. The vehicle groups were administered 0.5% CMC (vehicle, n=7), and the test groups of db/db mice and ob/ob mice were administered 10, 20, 50 mg/kg HD047703 and sitagliptin 10 mg/kg as a positive agent (n=7) QD, through 10 ml/kg, and 10, 30 mg/kg HD047703 (n=7) BID through 10 ml/kg, respectively. In DIO model groups, the vehicle groups were administered 0.5% CMC (vehicle, n=7) BID, and the test groups were administered 10, 20, 50 mg/kg HD047703 (n=7) BID through 10 ml/kg. During the treatment period, body weight of each animal was checked. At 4 weeks after initiating the administration of, the
OGTT was performed in the administrated mice. To assess the glucose-lowering effect of GLP-1 in DIO model groups, we measured the final body weight. The fat pads were immediately removed and their weights were measured.

**Statistical analysis**
Values are expressed as the mean standard error (SE). Group comparisons were carried out using one-way ANOVA with a Dunnett’s comparison test and two-way ANOVA. Statistical analyses were conducted using ‘GraphPad Prism 5’ software (Graphpad Co., La Jolla, CA, USA), and a \( p \)-value of <0.05 was considered to be statistically significant.

**RESULTS**

**Increase in the cAMP level by the GPR119 agonist**
The GPR119 signaling is known to be triggered by elevation of the cAMP synthesis. Therefore, we tested whether HD047703 elevates the intracellular cAMP level in CHO cells stably expressing the human GPR119 receptor. HD047703 significantly stimulated intracellular cAMP accumulation in a dose-dependent manner and showed an EC50 value of 110 nM for human GPR119-CHO stable cell lines (Fig. 1).

**Effect of single administration of HD047703 on glucose tolerance in normal mice**
We evaluated the role of HD047703 in the acute regulation of insulin secretion in vivo by examining the blood glucose level and GLP-1 secretion during the OGTT in normal mice.

We also tested whether elevation of the cAMP level by HD047703 increased the GLP-1 secretion. Overnight-fasted normal C57BL/6J mice were administered the 10, 50 mg/kg dose (Fig. 2C) of HD047703 before 30 min of glucose loading, then blood samples were collected after 20 min of glucose loading to analyze GLP-1 levels by ELISA. Sitagliptin, DPP-4 inhibitor, caused an increase in the plasma GLP-1 level (Fig. 2C, \( p < 0.001 \) vs. vehicle group), and an increased GLP-1 level may lead to improved glucose-stimulated insulin secretion. After administration of 50 mg/kg of HD047703, the plasma GLP-1 level was significantly increased (Fig. 2C, \( p < 0.05 \) vs. vehicle group).

**Effect of chronic treatment with HD047703 in diabetic db/db and ob/ob mice**
To evaluate the anti-diabetic efficacy of HD047703 in a diabetic model, 6-week-old diabetic db/db mice were treated with 10, 20, 50 mg/kg HD047703 or vehicle for 4 weeks. In the OGTT performed at 28 days after administration, the HD047703 treated groups showed lower blood glucose levels than the vehicle group, and AUC values during OGTT showed lower abundances in the vehicle group (Fig. 3A, B). In the 50 mg/kg HD047703 group, the glucose level was significantly decreased. To evaluate the efficacy of HD047703 in another type 2 diabetic model, 6-week-old diabetic ob/ob mice were treated with 10, 30 mg/kg HD047703 or vehicle for 4 weeks. In the OGTT performed at 28 days after administration, the HD047703 treated groups showed significantly lower blood glucose levels than the vehicle group in a dose-dependent manner, and AUC values during OGTT showed lower abundances in the vehicle group (Fig. 3C, D).

**Effect of chronic treatment with HD047703 in diabetic DIO mice**
To evaluate the effects of HD047703 on the combination of dietary and genetic influences, diabetic DIO mice were treated with 10, 20, 50 mg/kg HD047703 or vehicle for 4 weeks. In the OGTT performed at 28 days after administration, the HD047703 treated groups showed lower blood glucose levels
than the vehicle group, and AUC values during OGTT showed lower abundances in the vehicle group (Fig. 3E, F) and the body weight was decreased slightly but not significantly (Fig. 3G). Inguinal fat pad weight was decreased in a dose-dependent manner, but this decrease was not significant (Fig. 3H).
DISCUSSION

The incretin hormone GLP-1 is released in response to nutrient ingestion and it is required for maintenance of normal glucose homeostasis (Kreymann et al., 1987). Several orally effective GPR119 agonists have been discovered and reported to have anti-diabetic actions in animals (Yoshida et al., 2010) and in humans (Katz et al., 2012). Compared to other medications for T2DM, the advantage of incretin hormone-based therapy is not only improved glycemic control, but also loss of body weight (Amiel et al., 2008). Chronic treatment with exendin-4, a long acting GLP-1 analogue, in a rodent obesity model resulted in improved insulin sensitivity and loss of body weight (Ilitz et al., 2006). Unfortunately, all incretin hormone-based drugs do not cause loss of body weight. Although selective DPP-4 inhibitors have been reported to have strong effects on improving insulin sensitivity and glycemic control, some reports have stated that sitagliptin does not decrease body weight in obese subjects (Barnett et al., 2007; Raun et al., 2007). Moreover, selective DPP-4 inhibitors have adverse effects on the immune system, thus causing rheumatoid arthritis and pancreatitis (Bekur et al., 2010; Iyer et al., 2012; Yokota and Igaki, 2012).

In the present study, we identified a novel small-molecule GPR119 agonist, HD047703, which not only improved the blood glucose level but also did not cause body weight gain. The major sites of GPR119 expression are pancreatic beta cells and intestinal L cells. Its action begins by increasing intracellular cAMP levels, and this pathway leads to insulin or GLP-1 secretion by beta or L cells (Drucker et al., 1994; Chu et al., 2007). Treatment of the CHO stable cell line with HD047703 resulted in elevated cAMP levels. Therefore, the in vitro studies indicate that the GPR119 agonist increases intracellular cAMP levels in a dose-dependent manner leading to GLP-1 secretion.

Acute administration of HD047703 also increased the GLP-1 secretion in normal C57BL/6J mice, which is related to improved glycemic control in T2DM animal models (Bekur et al., 2010). These data suggest that HD047703 may activate GPR119, which regulates GLP-1 secretion in normal mice. Chronic administration of HD047703 in the db/db and ob/ob mouse models of T2DM resulted in improved glycemic control as long as the treatment was continued, suggesting that HD047703 may improve glycemic control. The DIO model resembles the human condition with respect to the combination of dietary as well as genetic influences on obesity and diabetes (Giorgino et al., 2011), and it also showed improved glycemic control. In addition, mice treated with HD047703 showed slight loss of body weight, although several studies have not shown this effect DPP-4 inhibitors on body weight (Barnett et al., 2007; Raun et al., 2007). In the OGTT performed at the 28th day, the HD047703 treated groups showed improved glucose tolerance compared to the vehicle-treated group. These data suggest that HD047703 improves glycemic control in the db/db, ob/ob, and DIO mice. GLP-1 agonists cause weight loss; conversely, the DPP-4 inhibitors appear to have a weight-neutral effect (Winzell and Ahrén, 2004). Also, body weight gain and inguinal fat pad weight were reduced in the HD047703 treated groups.

In conclusion, we evaluated a novel small-molecule GPR119 agonist, HD047703, which effectively reduced the glucose levels in normal and diabetic mice. A significant decrease was observed in the inguinal fat pad weight after in vivo chronic treatment. Although further studies on this compound are required, including the measurement of incretin hormone levels, and functional activity of β-cells and its proliferative activity, this study demonstrated that HD047703 can be a potential oral anti-diabetic agent that can improve glycemic control in the treatment of T2DM patients.

CONFLICT OF INTEREST

DH Kim and JK Phee are employees of Hyundai Pharm. Corp.

ACKNOWLEDGMENTS

This study was supported by ‘A Grant of Advance Technology Center’ (ATC; Project license: 10042208) of Korea Ministry of Knowledge and Economy.

REFERENCES

Amiel, S. A., Dixon, T., Mann, R. and Jameson, K. (2008) Hypoglycaemia in type 2 diabetes. Diabet. Med. 25, 245-254.
Barnett, A. (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract. 60, 1454-1470.
Barnett, A., Ailsworth, J., Jameson, K. and Mann, R. (2007) A review of the effects of antihyperglycaemic agents on body weight: The potential of incretin targeted therapies. Curr. Med. Res. Opin. 23, 1493-1507.
Bekur, R., Nagaraja, M. V., Shivashankara, K. N. and Stanley, W. (2010) Sitagliptin-induced hemolysis. Indian J. Pharmacol. 42, 320-321.
Chu, Z. L., Jones, R. M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M., Gao, H., Mondala, H., Bagnol, D., Unett, D., Liang, Y., Demarest, K., Semple, G., Behan, D. P. and Leonard, J. (2007) A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148, 2601-2609.
DeFronzo, R. A., Bona Donna, R. C. and Ferrannini, E. (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15, 318-368.
Drucker, D. J., Jin, T., Asa, S. L., Young, T. A. and Brubaker, P. L. (1994) Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol. Endocrinol. 8, 1646-1655.
Furman, B., Pyne, N., Flatt, P. and O’Harte, F. (2004). Targeting beta-cell cyclic 3′5′ adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. J. Pharm. Pharmacol. 56, 1477-1492.
Giorgino, F., Leonardi, A., Natalichio, A. and Laviola, L. (2011) Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J. Endocrinol. Invest. 34, 69-77.
Ho, J., Leung, A. K. and Rabi, D. (2011) Hypoglycemic agents in the management of type 2 diabetes mellitus. Recent Pat. Endocr. Metab. Immune Drug Discov. 5, 66-73.
Ilitz, J. L., Baker, D. E., Setter, S. M. and Keith Campbell, R. (2006) Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clin. Ther. 28, 652-665.
Jones, R. M. and Leonard, J. N. (2009) The emergence of GPR119 agonists as anti-diabetic agents. In Annual Reports in Medicinal Chem Vol 44 (J. E. Macor, Ed), pp149-170, Academic Press, Oxford.
Jones, R. M., Leonard, J. N., Buzard, D. J. and Lehmann, J. (2009) GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 19, 1339-1359.
Katz, L. B., Gambale, J. J., Rothenberg, P. L., Vanapalli, S. R., Vann-
aro, N., Xi, L., Sarich, T. C. and Stein, P. P. (2012) Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. *Diabetes Obes. Metab.* **14**, 709-716.

Kreymann, B., Williams, G., Ghatei, M. A. and Bloom, S. R. (1987). Glucagon-like peptide-1 7-36: A physiological incretin in man. *Lancet* **2**, 1300-1304.

Iyer, S. N., Drake, A. J. 3rd, West, R. L., Mendez, C. E. and Tanenberg, R. J. (2012) Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. *Endocr. Pract.* **18**, e10-13.

Meece, J. (2007) Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. *Curr. Med. Res. Opin.* **23**, 933-944.

Raun, K., von Voss, P., Gottfredsen, C. F., Golozoubova, V., Rolin, B. and Knudsen, L. B. (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-iv inhibitor, vildagliptin, does not. *Diabetes* **56**, 8-15.

Ross, S. A. and Ekoé, J. M. (2010). Incretin agents in type 2 diabetes. *Can. Fam. Physician* **56**, 639-648.

Taylor, S. I., Accili, D. and Imai, Y. (1994) Insulin resistance or insulin deficiency: Which is the primary cause of NIDDM. *Diabetes* **43**, 735-740.

Winzell, M. S. and Ahrén, B. (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. *Diabetes* **53**, S215-219.

Yokota, K. and Igaki, N. (2012) Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: A case report. *Intern. Med.* **51**, 2041-2044.

Xia, Y., Chackalamannil, S., Greenlee, W. J., Jayne, C., Neustadt, B., Stamford, A., Vaccaro, H., Xu, X. L., Baker, H., O’Neill, K., Woods, M., Hawes, B. and Kowalski, T. (2011) Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for the treatment of type 2 diabetes. *Bioorg. Med. Chem. Lett.* **21**, 3290-3296.

Yoshida, S., Tanaka, H., Oshima, H., Yamazaki, T., Yonetoku, Y., Oshi, T., Matsui, T. and Shibasaki, M. (2010) AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. *Biochem. Biophys. Res. Commun.* **400**, 745-751.